🔎 Trials Near Me

Home › NCT07191327

Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy

Recruiting

Testing Personalized High Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy

Who can join

Ages 50 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Diagnosis or symptoms consistent with PCA
* Fluent in English
* HD-tDCS compatible
* Stable on relevant medications for at least approximately 4 weeks prior to study enrollment
* If completing any additional, optional, long-term study visits in a remote location (i.e., not our office), a study partner is required in order to administer HD-tDCS. Those choosing to return to our office may have, but are not required to have, a study partner.

Exclusion Criteria:

* Other relevant neurological disease (e.g., epilepsy) or injuries (e.g., large vessel stroke, moderate-severe traumatic brain injury) viewed as primary to deficits since these could interfere with etiologic considerations and confound study results
* Active, relevant psychiatric conditions (e.g., bipolar disorder, schizophrenia) since the symptoms of these conditions may confound study participation.
* A recent (e.g., within the past 2 years) significant history of, or current, alcohol or drug abuse/dependence. Remote history of abuse/dependence is not exclusionary as long as it is not considered to be the primary etiology for visuospatial deficits.
* Women that are lactating/breastfeeding, pregnant, or may potentially be pregnant will be excluded from the study.

About the study

This study is being completed to learn if high-definition transcranial direct current stimulation (HD-tDCS) has an effect on visual and thinking abilities in persons with posterior cortical atrophy (PCA). Participants will be randomized to receive real or sham HD-tDCS (8 sessions over 4 days).

Following the randomized treatment, participants will have optional open-label phase with real HD-tDCS up to 26 weeks and other possible testing.

What is being tested

Sponsor: University of Michigan · Participants: 50 · Started: Jan 28, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07191327

Locations in the U.S.

MichiganUniversity of Michigan, Ann Arbor

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.